$435 Million is the total value of Foresite Capital Management II, LLC's 4 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TXG | Sell | 10x Genomics, Inc. | $407,889,000 | +15.1% | 2,253,528 | -10.0% | 93.76% | +0.2% |
| NVAX | Novavax, Inc. | $12,215,000 | +62.6% | 67,373 | 0.0% | 2.81% | +41.5% | |
| EPZM | Epizyme, Inc. | $8,710,000 | -19.8% | 1,000,002 | 0.0% | 2.00% | -30.2% | |
| XLRN | Acceleron Pharma Inc. | $6,222,000 | +6.0% | 45,884 | 0.0% | 1.43% | -7.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 29 | Q4 2021 | 11.9% |
| Acceleron Pharma Inc. | 24 | Q3 2021 | 4.8% |
| Aerie Pharmaceuticals, Inc. | 22 | Q1 2020 | 40.3% |
| 10x Genomics, Inc. | 17 | Q3 2023 | 100.0% |
| Aimmune Therapeutics, Inc. | 17 | Q3 2019 | 41.0% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 12.6% |
| Zafgen, Inc. | 12 | Q3 2017 | 33.5% |
| BioDelivery Sciences International, Inc. | 12 | Q1 2019 | 3.2% |
| Insmed Incorporated | 11 | Q1 2020 | 13.8% |
| Adaptimmune Therapeutics PLC | 9 | Q4 2018 | 11.3% |
View Foresite Capital Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-16 |
View Foresite Capital Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.